People: MELA Sciences Inc (MELA.O)

MELA.O on Consolidated Issue listed on NASDAQ Capital Market

1.07USD
17 May 2013
Price Change (% chg)

$-0.03 (-2.73%)
Prev Close
$1.10
Open
$1.09
Day's High
$1.09
Day's Low
$1.05
Volume
501,260
Avg. Vol
505,651
52-wk High
$4.37
52-wk Low
$1.02

Search Stocks

Summary

Name Age Since Current Position

Joseph Gulfo

 48 2011 Chairman of the Board, President, Chief Executive Officer

Richard Steinhart

 2006 Chief Financial Officer, Vice President - Finance, Treasurer, Secretary

Nikolai Kabelev

 35 2008 Vice President - Research & Development

David Stone

 55 2011 Lead Independent Director

Robert Coradini

 52 2011 Independent Director

Anne Egger

 59 2009 Independent Director

Mark Fabiani

 54 2011 Independent Director

John Goddard

 60 2011 Independent Director
» Insider Trading

Biographies

Name Description

Joseph Gulfo

 Dr. Joseph V. Gulfo is Chairman of the Board, President, Chief Executive Officer of MELA Sciences, Inc. He has served as President and Chief Executive Officer and a member of the Board of Directors since January 2004 and as Chairman since December 2011. From May 1999 to November 2003, he served as Chairman, Chief Executive Officer and President of Antigen Express, Inc., a development-stage company developing immunodiagnostics and therapeutics for cancer. Dr. Gulfo serves as a director of ProCertus BioPharm, Inc., a privately-held company. Dr. Gulfo received a B.S. in biology from Seton Hall University, an M.D. from the University of Medicine and Dentistry of New Jersey and an M.B.A. in finance from Seton Hall University.

Richard Steinhart

 Mr. Richard I. Steinhart is Chief Financial Officer, Vice President - Finance, Treasurer and Secretary of MELA Sciences, Inc. He has served as Vice President, Finance and Chief Financial Officer and Treasurer since April 2006 and as Secretary since November 2006. From May 1992 until joining the Company Mr. Steinhart was a Managing Director of Forest Street Capital/SAE Ventures, a boutique investment banking, venture capital, and management consulting firm focused on healthcare and technology companies. Prior to Forest Street Capital/SAE Ventures, he was Vice President and Chief Financial Officer of Emisphere Technologies, Inc. Mr. Steinhart’s other experience includes seven years at CW Group, Inc., a venture capital firm focused on medical technology and biopharmaceutical companies, where he was a General Partner and Chief Financial Officer. Until December 2011, Mr. Steinhart served on the Board of Manhattan Pharmaceuticals, Inc., a biopharmaceutical company and was Chairman of its Audit Committee. Mr. Steinhart began his career at Price Waterhouse, now known as PricewaterhouseCoopers. He holds B.B.A. and M.B.A degrees from Pace University and is a Certified Public Accountant.

Nikolai Kabelev

 Mr. Nikolai Kabelev is Vice President - Research & Development of MELA Sciences, Inc., since January 2008. Previously, since January 2007 he served as MelaFind® Project Team Leader. From June 2005 to present he has served as a Director, Algorithm and Software Development for the Company. Prior to that, and since June 1999, he worked for the Company as a Computer Scientist. Prior to joining the Company he worked at the Center for Telecommunication Research at Columbia University. He holds B.Sc. degree in Computer Science from Transport and Telecommunication Institute (Riga Aviation University), Latvia.

David Stone

 Mr. David K. Stone is Lead Independent Director of MELA Sciences, Inc., since December 8, 2011. In 2006, Mr. Stone founded Liberty Tree Advisors, LLC, a life sciences investment banking and consulting firm where he is a Managing Director. Prior to this, from 2000 to 2006 Mr. Stone was a Managing Director and Partner at Flagship Ventures, a venture capital fund focused in the life sciences industry. From 1989 to 1999, Mr. Stone led the biotechnology equity research team at Cowen & Company. Mr. Stone is on the Board of Directors of PAKA Pulmonary Pharmaceuticals and of Seahorse Bioscience, where he is Chairman of the Audit Committee. From 2001 to 2009, he served on the Board of Directors of Oscient Pharmaceuticals, where he served as Chairman from 2005 to 2009.

Robert Coradini

 Mr. Robert Coradini is an Independent Director of MELA Sciences, Inc., since December 8, 2011. Prior to this and since 1996 Mr. Coradini served in executive capacities at several Johnson & Johnson (“J&J”) Companies. From June 2005 to May 2009, Mr. Coradini served as President of New Ventures for J&J Consumer Products Company which included and growing OrthoNeutrogena (aka OrthoDermatologics), a in dermatology care, from January 2006 thru May 2009. From January 2003 through June 2005, Mr. Coradini served as President of CardioVations/Ethicon, a J&J Company with cardiac surgery and tissue management. From June 2000 to January 2003 Mr. Coradini was President of Lifescan, a J&J Company that provides medical devices to the diabetes market. Before Lifescan, Mr. Coradini was head of Business Development for J&J’s Medical Devices & Diagnostic Group and before that President of Cordis Endovascular. Prior to J&J, Mr. Coradini was with General Electric for ten years, seven of which were with GE Medical Systems. Mr. Coradini serves on the Board of Directors of WaferGen BioSystems and Chairs its Nominating and Governance Committee and is a member of its Compensation Committee.

Anne Egger

 Ms. Anne Egger is an Independent Director of MELA Sciences, Inc., since June 2009. Ms. Egger has served as Vice President of Sales and Marketing of TopMD, a dermatology products company, since March 2012. Since March 2009, Ms. Egger has been the owner/director of AME Enterprises, LLC, a pharmaceutical consulting company. From October 1988 until her retirement in March of 2009, Ms. Egger served as head of the U.S. Sales and Marketing division of Galderma Laboratories, a joint venture between Nestlé and L’Oréal. Ms. Egger was an Industry Adjunct member of the American Academy of Dermatology for the past 8 years and a member of the American Society of Dermatologic Surgeons Industry Council for the last 6 years.

Mark Fabiani

 Mr. Mark Fabiani is an Independent Director of MELA Sciences, Inc., since December 8, 2011. Mr. Fabiani is a Principal of Mark Fabiani LLC, a crisis management consulting firm, where he has served since 1997. Mr. Fabiani was formerly Special Counsel to President Clinton, Deputy Campaign Manager for Vice President Al Gore, and Deputy Assistant Attorney General at the Justice Department.

John Goddard

 Mr. John Geoffery Goddard is an Independent Director of MELA Sciences, Inc., since December 8, 2011. Since June 2011, Mr. Goddard has served as non-executive director of Optos PLC, a British medical devices company. Mr. Goddard was formerly Chief Financial Officer AstraZeneca’s US operations and from April 2006 to March 2010, he was Head of Business Development and Group Strategy of AstraZeneca PLC. Mr. Goddard serves on the Board of Directors of Optos PLC and is a member of its Audit Committee, as well as a non-executive director of an Indian company, Intas Pharmaceuticals Limited. From February 2008 to June 2011, Mr. Goddard was non-executive director of Renovo Group PLC, a British pharmaceutical company. Mr. Goddard is a Chartered Accountant in the UK and Wales.

Basic Compensation

Name Fiscal Year Total

Joseph Gulfo

 359,008

Richard Steinhart

 484,800

Nikolai Kabelev

 370,900

David Stone

 --

Robert Coradini

 --

Anne Egger

 --

Mark Fabiani

 --

John Goddard

 --
As Of 30 Dec 2011

Options Compensation

Name Options Value

Joseph Gulfo

 173,724 536,498

Richard Steinhart

 0 0

Nikolai Kabelev

 0 0

David Stone

 0 0

Robert Coradini

 0 0

Anne Egger

 0 0

Mark Fabiani

 0 0

John Goddard

 0 0

Insider Trading

Name Shares Traded Price

GULFO JOSEPH V

 25,000 $1.08

GULFO JOSEPH V

 20,000 $1.15

KABELEV NIKOLAI

 2,886 $1.00

GULFO JOSEPH V

 10,000 $2.68

GODDARD JOHN GEOFFREY

 10,000 $2.90

GULFO JOSEPH V

 10,000 $3.88

KABELEV NIKOLAI

 1,875 $1.00

CORADINI ROBERT

 21,457 $3.97

GULFO JOSEPH V

 21,458 $3.97

CHRYSSIS GEORGE C

 10,000 $0.00

BRAGINSKY SIDNEY

 10,000 $0.00

CASTLEMAN BREAUX

 10,000 $0.00

WAGNER GERALD D

 10,000 $0.00
» Full list on Insider Trading
Search Stocks